Clinical trial
A Phase 1 Study of Talimogene Laherparepvec and Panitumumab in Patients With Locally Advanced Squamous Cell Carcinoma of the Skin (SCCS)
NCT04163952 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of Talimogene Laherparepvec and Panitumumab in Patients With Locally Advanced Squamous Cell Carcinoma of the Skin (SCCS)
- Lead sponsor
- Rutgers, The State University of New Jersey
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 31, 2020
- Completion date
- March 28, 2025
- Enrollment
- 5 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced skin squamous cell carcinoma, metastatic skin squamous cell carcinoma, recurrent skin squamous cell carcinoma